Johnson & Johnson JNJ

$270.68 +1.51 (0.56%)

Valuation

Market cap
648,672,256,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.79
Forward PE
23.19
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,323,700
Avg volume
6,959,354
Day's range
$269.01 – $275.23
Shares out
2,409,898,000
Stochastic %K
69%
Beta
0.24
Analysts
Strong Sell
Price target
$281.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

BioTechHealthX Sep 25, 7:28 AM
$ARAY $SSII $BDX $GMED $JNJ Surgical robots get the headlines, but pharmacy automation and robotic cancer treatment belong in the conversation too. See which 10 stocks made the best medical stocks ranking. https://biotechhealthx.com/biotech-news/top-10-medical-robotics-stocks-to-buy-today/
0 replies
SignalYieldAI Sep 25, 6:57 AM
📊 Week in Review Markets stayed rangebound (S&P 7,600-7,800), yields held near 19-year highs, Trump-Xi summit Thursday came without a clear catalyst. Nasdaq held up better than Dow this week. Market Context: 54.7/100, Caution. Cycle Risk strong (88), but Valuation weak (19/100, Buffett Indicator 247.9%), Insider Sentiment at rock bottom (0/100). Real yield check (CPI 3.35% barrier): Gold Futures winning clearly, 11.89% real yield, best on the board. $PLD and $JNJ actually running negative real yield right now. Credit spreads stay Normal. Analyst actions this week: $MU got another huge target bump (Wells Fargo $1,400, on top of Citi's $1,300 earlier). $MSFT upgraded Hold→Buy at Stifel ($575). $NFLX downgraded Buy→Hold at HSBC. BCA Research note worth remembering: history shows the S&P has posted strong gains across most Fed hiking cycles.
0 replies
Alwaysdiversify Sep 24, 7:54 PM
$SLS With $JNJ at an all-time high and up over 50% on the year, it just seems so ripe now for the company to use its stock for a sizable chunk of any acquisition. At a minimum, they sure are in a much better financial position than a year ago to acquire SLS.
0 replies
Johnmtnb2018 Sep 24, 7:53 PM
$SLS $JNJ Where is the kid that said the deal is done and he’s going on long vacation yesterday? Is that you Angelos?
0 replies
Johnmtnb2018 Sep 24, 7:49 PM
$SLS $JNJ Looking like deal is done !
0 replies
Johnmtnb2018 Sep 24, 7:47 PM
$JNJ $SLS Margin calls coming for shorts. Angelos set up a Short trap for the ages !
0 replies
Johnmtnb2018 Sep 24, 7:39 PM
$JNJ $SLS Basic Stats Short Interest Statistics Short Interest 57,926,912 Shares - source: NASDAQ Short Interest Ratio 11.73 Days to Cover Looking like Shorts just ran out of time !
0 replies
Johnmtnb2018 Sep 24, 7:26 PM
$SLS $JNJ Trading like JNJ knocked Angelos off his tracks !
0 replies